<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Tregs on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/tregs/</link><description>Recent content in Tregs on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Thu, 15 Oct 2026 05:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/tregs/index.xml" rel="self" type="application/rss+xml"/><item><title>TCR-Tregs: Antigen-Specific Cell Therapy</title><link>https://rheumatologydigest.org/posts/tcr-tregs-cell-therapy/</link><pubDate>Thu, 15 Oct 2026 05:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/tcr-tregs-cell-therapy/</guid><description>TCR-Tregs aim to restore tolerance rather than delete B cells, but the data are preclinical and manufacturing is the barrier to access.</description></item></channel></rss>